Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Lipid Mediators and Cell Signalling

• Publication date

  1997-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0929-7855(97)00011-4PMID 9302650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective effects of Yangambin - a naturally occurring platelet-activating factor (PAF) receptor antagonist - on anaphylactic shock in rats.

  1996cited by this paper
• Yangambin: A New Naturally-Occurring Platelet-Activating Factor Receptor Antagonist: Binding and In Vitro Functional Studies

  1995cited by this paper
• Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies.

  1995cited by this paper
• Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.

  1994cited by this paper
• Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia.

  1994cited by this paper
• Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial

  1994cited by this paper
• Platelet-activating factor antagonists as therapeutic strategy in sepsis.

  1994cited by this paper
• Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.

  1994cited by this paper
• [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.

  1994cited by this paper
• Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.

  1993cited by this paper
• Multiple organ failure. Pathophysiology and potential future therapy.

  1992cited by this paper
• Platelet-activating factor antagonists in experimental shock.

  1992cited by this paper
• Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.

  1992cited by this paper
• Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.

  1992cited by this paper
• Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents.

  1991cited by this paper
• Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.

  1991cited by this paper
• Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung

  1991cited by this paper
• Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.

  1991cited by this paper
• Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.

  1991cited by this paper
• Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms.

  1990cited by this paper
• Effects of the PAF antagonist WEB 2086 on PAF-induced physiologic alterations and on IgE anaphylaxis in the rabbit.

  1990cited by this paper
• Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators.

  1990cited by this paper
• Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms.

  1990cited by this paper
• Platelet activating factor and human disease

  1989cited by this paper
• Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

  1987cited by this paper
• Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

  1987cited by this paper
• A lethal role of platelet activating factor in anaphylactic shock in mice.

  1987cited by this paper
• Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes.

  1987cited by this paper
• Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study.

  1987cited by this paper
• PAF-acether today--relevance for acute experimental anaphylaxis.

  1987cited by this paper
• Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021.

  1986cited by this paper
• Species difference in the specific receptors of platelet activating factor.

  1986cited by this paper
• Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes

  1986cited by this paper
• Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

  1985cited by this paper
• Synthesis of PAF-acether and blood volume changes in gram-negative sepsis.

  1985cited by this paper
• Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig.

  1984cited by this paper
• Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader.

  1981cited by this paper
• Isolation of lymphocytes, granulocytes and macrophages.

  1976cited by this paper
• Estimation of hormone receptor affinity by competitive displacement of labeled ligand: effect of concentration of receptor and of labeled ligand.

  1975cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

  1962cited by this paper

• Challenges in Developing a Safe Nanomedicine based on Ocotea Duckei Vattimo to Leishmaniasis Treatment: Methodology, Nanoparticle Development and Cytotoxicity Assays

  2014cites this paper
• Platelet-activating factor (PAF)-antagonists of natural origin.

  2013cites this paper
• Traumatic Brain Injury-Associated Coagulopathy

  2012cites this paper
• Immunoregulatory Protein Profiles of Necrotizing Enterocolitis versus Spontaneous Intestinal Perforation in Preterm Infants

  2012cites this paper
• From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.

  2010cites this paper
• Neolignans from plants in northeastern Brazil (Lauraceae) with activity against Trypanosoma cruzi.

  2010cites this paper
• GC-MS analysis and cardiovascular activity of the essential oil of Ocotea duckei

  2008cites this paper
• Yangambin Cytotoxicity: A Pharmacologically Active Lignan Obtained from Ocotea duckei Vattimo (Lauraceae)

  2008cites this paper
• Crude Ethanolic Extract, Lignoid Fraction and Yangambin from Ocotea duckei (Lauraceae) Show Antileishmanial Activity

  2007cites this paper
• Biological Activity of Yangambin on the Postembryonic Development of Chrysomya megacephala (Diptera: Calliphoridae)

  2007cites this paper
• Morphoanatomical study of the leaves of Ocotea duckei Vattimo (Lauraceae-Lauroideae)

  2006cites this paper
• Cardiovascular properties of yangambin, a lignan isolated from Brazilian plants.

  2006cites this paper
• Atividade antimicrobiana "in vitro" e determinação da concentração inibitória mínina (CIM) de fitoconstituintes e produtos sintéticos sobre bactérias e fungos leveduriformes

  2006cites this paper
• Central nervous system activity of yangambin from Ocotea duckei Vattimo (Lauraceae) in mice

  2005cites this paper
• Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.

  2005cites this paper
• Evaluation of the mutagenic potential of yangambin and of the hydroalcoholic extract of Ocotea duckei by the Ames test.

  2003cites this paper
• New findings on the bioactivity of lignans

  2002cites this paper
• Yangambin, a lignan obtained from Ocotea duckei, differentiates putative PAF receptor subtypes in the gastrointestinal tract of rats.

  2000cites this paper
• The contractile action of platelet-activating factor on gallbladder smooth muscle.

  2000cites this paper
• OCOTEA DUCKEI : EXCEPTIONAL SOURCE OF YANGAMBIN AND OTHER FUROFURAN LIGNANS

  1999cites this paper
• FURTHER LIGNANS FROM OCOTEA DUCKEI

  1999cites this paper